Newsletters

2022 TECHNICAL BULLETINS:

Biocompatibility and Devices

Biocompatibility is the ability of an implant material to function in vivo without eliciting detrimental local or systemic responses in the body. Prior to their use in human fracture fixation, biomaterials undergo tissue and animal testing to determine their safety and efficacy. We offer a range of safety evaluation and biocompatibility services for medical devices.

2021 TECHNICAL BULLETINS:

Dermal Burn Modeling

Due to Comparative Biosciences, Inc. unique and extensive experience in dermatology studies and state-of-theart facilities, we have the skill and expertise to accelerate new dermatology drugs, biologics, and devices from discovery through the drug development process, to regulatory submission and studies in man.

2021 TECHNICAL BULLETINS:

Surgical Models and Services

Comparative Biosciences, Inc. currently offer a variety of surgical models and services on multiple rodent species (rat, mouse, guinea pig, hamster, and gerbil) at several of our AAALAC-accredited production facilities in North America.

2021 TECHNICAL BULLETINS:

Subcutaneous Implant Procedure + Video

In medicine, a subcutaneous implant, or subcutaneous pellet, is an implant that is delivered under the skin into the subcutaneous tissue by surgery or injection and is used to deliver a drug for a long period of time. Watch our video procedure!

2021 TECHNICAL BULLETINS:

Intraocular Lens Implantation

Comparative Biosciences, Inc. provides a range of sophisticated and customized intraocular implant models. We are offering intraocular lens implantation surgery for cataract treatment particularly in both pigmented and albino rabbits.

2019 TECHNICAL BULLETINS:

Oxygen Induced Retinopathy

Our highly specialized staff is experienced in providing exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathology/immunohistochemistry related to the eye.

2019 TECHNICAL BULLETINS:

Dermatology Studies

Due to CBI’s unique and extensive experience in dermatology studies and state-of-theart facilities, we have the skill and expertise to accelerate new dermatology drugs, biologics, and devices from discovery through the drug development process, to regulatory submission and studies in man.

2019 TECHNICAL BULLETINS:

CBI Overview

A Contract Research Organization by Scientists, for Scientists.

Comparative Biosciences, Inc., a premier preclinical contract research organization (CRO), is committed to providing expert high-quality contract research services to all sectors of the biomedical community. Extensive experience in the biotechnology and pharmaceutical industries provides our staff with a solid track record in preclinical research and drug development capabilities.

January 2019

Intraocular Lens Implantation Studies

Intraocular Lens Implantation Preclinical Models at CBI. CBI provides a range of sophisticated and customized intraocular implant models.

December 2018

Pompe Disease Studies

Pompe disease is caused by pathogenic variations in the acid alpha-glucosidase (GAA) gene. Close to 500 different GAA gene variations have been identified in families with this disorder.

Glycogen Storage Disease Histopathology on Human Muscle Biopsies from patients affected with a Glycogen Storage Disease.

November 2018

Fibrosis Inflammation Studies

Tissue damage and inflammation are important triggers for regeneration and fibrosis.

CBI focuses on the pathways leading from tissue damage to inflammation, from inflammation to fibrosis and from fibrosis to function.

June 2018

Central Nervous System Studies

CBI offers a variety of customized, investigative, and specialized surgical CNS pharmacology and efficacy models.

If you have a specialized CNS study requirement, our skilled scientists can facilitate the protocol development as well as the conduct of these novel, difficult and specialized projects.

Visit CBI at SOT 2018 – Annual Meeting and Tox Expo

SOT 2018 March 11 – 15 San Antonio, Texas

February 2018

Bronchopulmonary Dysplasia

CBI Congratulates Meridigen Biotech Co., Ltd on their successful IND for their project!

January 2018

Scleroderma in Tight Skin Mouse Model

CBI offers preclinical research studies in dermal and pulmonary fibrosis. In addition to our validated bleomycin-induced fibrosis models, we also now offer fibrosis studies utilizing the JAX Tight Skin Mouse Model.

December 2017

Toxicology Capabilities: From Discovery to IND

CBI offers a complete program of preclinical research services to support a range of your toxicology requirements. We have experience with early
assessment of new molecules including single dose, multiple dose and targeted studies, as well as directed or investigative toxicology, and IND enabling toxicology programs.

August 2017

Dermal Pharmacology and Toxicology at CBI

Check out our latest updates on our pharmacology models and toxicology capabilities in dermatology.

July 2017

Otic and Auditory Studies at CBI

Comparative Biosciences continues to evolve with niche and specialty preclinical, IND enabling GLP or non-GLP otic and auditory toxicology, efficacy, pharmacokinetics/pharmacodynamics in relevant animal species.

June 2017

See you at ARVO 2017!

CBI will be attending the ARVO annual meeting in Baltimore, MD this year. Please contact our business development team to set up a meeting about your upcoming research needs!

May 2017

Dermatology Capabilities

As the largest organ in the human body, skin plays a vital role in overall health and well-being. With over 20 years of experience, Comparative Biosciences has an arsenal of innovative and validated pharmacological models for dermatological therapeutics.

April 2017

Hyperoxygenation Models at CBI

Clinical indications caused by neonatal hyperoxygenation such as bronchopulmonary fibrosis and retinopathy of prematurity have created an unmet medical need for therapeutic treatments. Comparative Biosciences has multiple robust and validated methods, ready to advance your therapeutic development.

March 2017

Visit Us at SOT

CBI will be attending SOT for our 20th year! Stop by booth #1932 and speak to our expert team about your upcoming preclinical research needs! Look for our poster at the show! Our very own Dr. Laine Ooi will be presenting a poster for our hyperoxia-induced pulmonary dysplasia model.

February 2017

Ocular Toxicology Services

Whatever your ocular study needs, Comparative Biosciences has the answer. With over 20 years of proficiency in the preclinical sphere, we have experience and expertise that you can count on.

January 2017

Comparative Biosciences’ 20th Anniversary

CBI was founded in 1996 by three partners in Santa Clara, CA. We conducted our first GLP study in 1997 and later expanded to our state-of-the-art purpose built facilities in Sunnyvale, CA. Our initial focus involved specialty services, and we continue this dedication 20 years later. This month we are celebrating our 20th anniversary.

August 2016

Diabetic Retinopathy Model

CBI has been helping our Sponsors with developing ocular therapies for 20 years. CBI’s experience and our Sponsors’ innovations are leading to new therapies and clinical trials to advance treatment of ocular diseases.

July 2016

Gene Therapy

Comparative Biosciences is your resource for preclinical Ocular Gene Therapy and Regenerative Medicine Studies.

Focusing on Oncology Studies

CBI has evaluated many potential anti-cancer compounds, our in-house expertise allows us to optimally design studies that provide critical pre-clinical efficacy data. Our custom study plans meet your research needs and prepare you for regulatory submission.

January 2016

New Products in Imaging Capabilities

CBI is proud to announce expanded capabilities in imaging to support discovery, exploratory, pharmacology and toxicology studies. We are able to provide the following new imaging capabilities to support your in-vivo preclinical studies: Dermal Fibrosis, LDI (Laser Doppler Instrument), OCT Optical Coherence Tomography), IVS Imaging and PET Scanning, MRI, Digital Radiology, CT and MicroCT

November 2015

NIH Expo and Grant Support

Visit us at the NIH research festival exhibit in Bethesda, MD, booth #1013. We are also continuing with grant support, from letters of support to collaboration and good faith pricing. Let’s partner together.

September 2015

Oxygen Induced Retinopathy

August 2015

Using Optical Coherence Tomography (OCT) in Ocular Studies

Optical Coherence Tomography, or “OCT” is a technique for obtaining sub-surface images of translucent or opaque materials at a resolution equivalent to a low-power microscope. It reveals or detects subtle changes, particularly in the eye, that are not visible by other means such as with slit lamp biomicroscopy or funduscopy.
Watch the OCT Demonstration Video

July 2015

In situ Hybridization

In situ hybridization (ISH) is a technique used to detect and localize the precesnce or absence of a specific genetic sequence in tissue using a probe with a complementary polynucleotide sequence.
Comparative Biosciences, Inc. offers both fluprescent (FISH) and chromogenic (CISH) is situ hybridization assays.
In Situ Hybridization Studies | Histopathology Studies

June 2015

Xenograft Studies

Xenografts of human tumor tissue into laboratory animal species provide a more accurate model of tour growth and activity administered drugs than in vitro studies. Comparative Biosciences, Inc. offers in vivo xenograft services to conduct drug development for oncology, playing a major role in development of new anti-cancer medicines and therapies.
Xenograft Studies | Histological | Antibacterial Research & Consulting

March 2015

Pre-clinical Studies in Atherosclerosis

Atherosclerosis is present in nearly 52% of americans and represents a huge unmet medical need. It occurs when fat, cholesterol and other substances build up in the walls of arteries and form hard structures called plaques. For companies investigating this disease and its associated symptoms, Comparative Biosciences, Inc. offers efficacy models and studies.C
Contact us for more information on Atherosclerosis studies.
Pharmacology | Atherosclerosis Studies | Antibacterial Research & Consulting

February 2015

Investigational New Drug Application Approved

Congratulations to all of our clients and colleagues who have launched successful INDS this past year! Comparative Biosciences, Inc. leader in stem cell pharmacology and GLP Toxicology congratulates our friends and colleagues on their IND successes in 2014, Viacyte, Xeris Pharmaceuticals, Celdara Medical and UCSD.

Contact us to discuss your complex IND needs.ust completed a long term ocular implant, and a long term dermal toxicity as well as numerous burn studies.
Pharmacology | Stem Cell Research | Antibacterial Research & Consulting

January 2015

Optimal Preclinical Research

Mini-pigs are being used for toxicology and for a wide variety of pharmacology modeling. Comparative Biosciences, Inc. just completed a long term ocular implant, and a long term dermal toxicity as well as numerous burn studies.
Optical Coherence Tomography (OCT) | Thermal Burn Modeling | Antibacterial Research & Consulting

December 2014

DermalOCT and Corneal Study

CBI Dermal OCT Scanning is used in our biomedical research, pharmacology and toxicology, including GLP studies. Our system enables new research opportunities. Applications include Ocular, Skin Models, Xenografts, Rodent Ears, and Tissue Engineering.
Optical Coherence Tomography (OCT) | Stem Cell Research | Antibacterial Research & Consulting

November 2014

Histopathology

CBI provides contract histology, immunohistochemistry, and pathology services to the biopharmaceutical industry. Whether preparing a single biopsy, a complex histomorphometry study or a complete carcinogenicity study, CBI offers high quality slide preparation, pathological evaluation, and reporting in a timely and cost effective manner. Histopathology is clearly one of the most important tools for assessment of drug efficacy and activity.
Histology Laboratory Capabilities | Immunohistochemistry | Pathology

October 2014

New Hope for Diabetes Patients

CBI is the industry leader in conducting difficult and complicated IND enabling and research studies with Stem Cells and Stem-Cell Device combination studies. We have conducted these complex studies in multiple species and for durations exceeding 1.5 years.
Stem Cell Research | Pharmacology | Antibacterial Research and Consulting

September 2014

Melanin Associated Antigen

CBI is offering for the month of September/October MAA Ocular INFLAMMATION modeling in rats that recapitulates the human disease of Anterior Uveitis.

September 2014

Ocular Toxicology Studies

CBI offers both exploratory proof-of-concept toxicity and tolerability studies and complete preclinical studies. We are also offering OCT intraocular assessments.

August 2014

Burns, Wound Healing and Fibrosis

CBI is developing the models to test the therapeutics that could accelerate the wound healing process. Learn more about our thermal burn modeling services and are Dermal Pharmacology and Efficacy Studies.

June 2014

Ocular Research and Toxicology

CBI provides a wrap-up from ARVO and is now offering OCT intraocular assessments as well as IOP, ERG and angiography.

May 2014

Ophthalmology

CBI provides exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathalogy/immunohistochemistry related to the eye. We are now also offering Optical Coherence Tomography (OCT) for research and toxicology studies. We will be exhibiting at The Association for Research in Vision and Ophthalmology (ARVO) next week, May 4-8, 2014 at booth #338, please stop by.

April 2014

Toxicology

CBI offers a complete program of preclinical research services to support a range of toxicology including: Acute, Subacute and Chronic Toxicity Studies-IND Enabling, Discovery and early Toxicology, Investigative, Ocular, Otic and Dermal Toxicology, Stem Cell Toxicology and many more. We also have a variety of special equipment and capabilities to supplement our regular toxicology.

March 2014